Literature DB >> 10197164

Expression of NG2/human melanoma proteoglycan in human adult articular chondrocytes.

K S Midwood1, D M Salter.   

Abstract

OBJECTIVE: NG2 is a transmembrane chondroitin sulfate (CS) rich proteoglycan originally identified in rats. It has recently been shown to be identical to human melanoma proteoglycan (HMPG). In rats NG2 has a limited distribution in adult tissues, being expressed predominantly by neuronal and glial cells whereas during development it is also expressed in developing mesenchyme including cartilage. NG2/HMPG has putative roles in interactions between glial and melanoma cells with extracellular matrix (ECM) molecules. This study was undertaken to assess whether NG2/HMPG was expressed by normal and osteoarthritic human articular chondrocytes.
DESIGN: Cryostat sections of human fetal knee joints and normal and osteoarthritic articular cartilage were immunostained with antibodies against rat NG2 (N143.8) and HMPG (M28B5, 9.2.27). Immunoprecipitation and Western blotting was carried out on protein extracts of chondrocytes from normal and osteoarthritic cartilage. Immunofluorescence of NG2 and potential ligands was carried out in vitro on cells from normal and osteoarthritic cartilage.
RESULTS: Fetal and both normal and osteoarthritic adult cartilage showed strong immunoreactivity for NG2/HMPG. Western blotting showed a smeared component of molecular weight greater than 400 kDa and a faint band at 250 kDa which became predominant upon digestion with chondroitinase ABC. Immunofluorescence of chondrocytes in vitro showed NG2 to be distributed in a punctate pattern without co-localization of actin or several ECM proteins including fibronectin and type VI collagen.
CONCLUSION: NG2/HMPG is expressed by human fetal and adult chondrocytes and in adult articular chondrocytes the core protein is chondroitin sulfated. The function of this molecular in human articular cartilage remains to be defined.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10197164     DOI: 10.1053/joca.1998.0128

Source DB:  PubMed          Journal:  Osteoarthritis Cartilage        ISSN: 1063-4584            Impact factor:   6.576


  9 in total

Review 1.  CSPG4, a potential therapeutic target, facilitates malignant progression of melanoma.

Authors:  Matthew A Price; Leah E Colvin Wanshura; Jianbo Yang; Jennifer Carlson; Bo Xiang; Guiyuan Li; Soldano Ferrone; Arkadiusz Z Dudek; Eva A Turley; James B McCarthy
Journal:  Pigment Cell Melanoma Res       Date:  2011-12       Impact factor: 4.693

2.  NG2, a novel proapoptotic receptor, opposes integrin alpha4 to mediate anoikis through PKCalpha-dependent suppression of FAK phosphorylation.

Authors:  N E Joo; T Watanabe; C Chen; M Chekenya; W B Stallcup; Y L Kapila
Journal:  Cell Death Differ       Date:  2008-02-22       Impact factor: 15.828

3.  Functional roles of CSPG4/NG2 in chondrosarcoma.

Authors:  Nuor S M Jamil; Asim Azfer; Harrison Worrell; Donald M Salter
Journal:  Int J Exp Pathol       Date:  2016-06-12       Impact factor: 1.925

Review 4.  CSPG4: a prototype oncoantigen for translational immunotherapy studies.

Authors:  Valeria Rolih; Giuseppina Barutello; Selina Iussich; Raffaella De Maria; Elena Quaglino; Paolo Buracco; Federica Cavallo; Federica Riccardo
Journal:  J Transl Med       Date:  2017-07-01       Impact factor: 5.531

5.  Neuron/Glial Antigen 2-Type VI Collagen Interactions During Murine Temporomandibular Joint Osteoarthritis.

Authors:  Mamoru Yotsuya; Andrew E Bertagna; Nageeb Hasan; Scott Bicknell; Toru Sato; David A Reed
Journal:  Sci Rep       Date:  2019-01-11       Impact factor: 4.379

6.  Clinical-Scale Production of CAR-T Cells for the Treatment of Melanoma Patients by mRNA Transfection of a CSPG4-Specific CAR under Full GMP Compliance.

Authors:  Manuel Wiesinger; Johannes März; Mirko Kummer; Gerold Schuler; Jan Dörrie; Beatrice Schuler-Thurner; Niels Schaft
Journal:  Cancers (Basel)       Date:  2019-08-16       Impact factor: 6.639

Review 7.  Theranostic impact of NG2/CSPG4 proteoglycan in cancer.

Authors:  Pier Andrea Nicolosi; Alice Dallatomasina; Roberto Perris
Journal:  Theranostics       Date:  2015-02-15       Impact factor: 11.556

Review 8.  The Role of NG2 Proteoglycan in Glioma.

Authors:  Sridevi Yadavilli; Eugene I Hwang; Roger J Packer; Javad Nazarian
Journal:  Transl Oncol       Date:  2016-02       Impact factor: 4.243

Review 9.  Chondroitin Sulfate Proteoglycan 4 and Its Potential As an Antibody Immunotherapy Target across Different Tumor Types.

Authors:  Kristina M Ilieva; Anthony Cheung; Silvia Mele; Giulia Chiaruttini; Silvia Crescioli; Merope Griffin; Mano Nakamura; James F Spicer; Sophia Tsoka; Katie E Lacy; Andrew N J Tutt; Sophia N Karagiannis
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.